Often a result of battlefield injury, uncontrolled internal bleeding is one of the leading causes of preventable death after trauma. Harvard Griffin GSAS and Harvard SEAS bioengineering PhD candidate Maithili Joshi has developed a groundbreaking treatment for these wounds: an injectable, self-assembling peptide that rapidly targets internal bleeding, binds to platelets, and accelerates clotting—without affecting normal blood function. Demonstrated to reduce blood loss by up to 90% in preclinical models, this innovation could redefine emergency trauma care by stabilizing patients when every second counts.
This research is funded by the U.S. Department of Defense, the Harvard John A. Paulson School of Engineering and Applied Sciences, and the Wyss Institute at Harvard University.
